MAR 25, 2019 10:36 AM PDT

Investigational Drug Reverses High Cholesterol and Non-Alcoholic Fatty Liver Disease

WRITTEN BY: Nouran Amin

A novel molecular pathway was recently discovered for an enzyme inhibitor in humans that is implicated in the development of high cholesterol and nonalcoholic fatty liver disease. Such conditions were found to be reversed in a mouse model using an investigational oral drug. The drug is known as TM5614 and is reported in a new research study to impede the actions of a multifunctional protein in the body known as plasminogen activator inhibitor 1, or PAI-1.

"High blood levels of PAI-1 are a hallmark of obesity, type 2 diabetes and metabolic syndrome, a cluster of risk factors for obesity-related diseases," said the study's lead researcher, Joshua Levine, M.D., Ph.D., an endocrinology fellow at Northwestern.

Learn more about non-alcoholic fatty liver disease:

The study was conducted based on findings that individuals who inherited a loss-of-function mutation in the gene that codes for PAI-1 have developed lower fasting insulin levels than those with unaffected relatives and appear protected from developing diabetes. Therefore, researchers were curious to see if blocking PAI-1 could reverse diet-induced obesity and its related health problems.

Specifically, the study investigated induced obesity in mice by feeding them a high-fat, high-sugar mice chow equivalent to fast food. Mice were then treated with the PAI-1 inhibitor TM5614. Results showed that after a week of treatment, the mice had improved fasting levels of blood sugar, insulin and LDL, or "bad" cholesterol, in compassion to untreated mice. Additionally, treated mice exhibited a "remarkable" reduction in fatty liver disease.

Learn more about LDL, “bad” cholesterol:

"This is important because PCSK9 inhibitors are the newest drug therapy available for the treatment of high cholesterol for people who do not benefit enough from statin cholesterol-lowering medicines or cannot tolerate statins," Levine said. "However, the high cost of these drugs limits their use, and they are injections, rather than pills. The drug may eventually become a less expensive and easier alternative to PCSK9 inhibitors."

Source: The Endocrine Society

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 22, 2019
Health & Medicine
NOV 22, 2019
Federal Government Weighs in on Marijuana and Opioid Addiction
The U.S. government is weighing in on the hot topic of whether or not medical marijuana is a successful tool in treating opioid addiction by barring the us...
NOV 23, 2019
Drug Discovery & Development
NOV 23, 2019
Drug Seeks To Target Treatment-Resistant Epilepsy
Ever imagined a world where you cannot shower alone, drive by yourself, and even go to work in fear of having the next seizure that can incapacitate you? U...
DEC 23, 2019
Drug Discovery & Development
DEC 23, 2019
FDA Approves New Schizophrenic Drug
The US Food and Drug Administration (FDA) has approved an atypical antipsychotic Caplyta (lumateperone; Intra-Cellular Therapies) for the treating schizoph...
JAN 16, 2020
Health & Medicine
JAN 16, 2020
Babies in Africa Receive World's First Malaria Vaccine
Would you accept a vaccine that was only 40% effective? For those at risk of malaria, the answer is likely a resounding, "yes!" According to the...
FEB 04, 2020
Cancer
FEB 04, 2020
The role of SRR in colorectal cancer
Researchers from Osaka University have recently discovered a new function of the multifunctional enzyme entitled serine racemase (SRR). According to the te...
FEB 10, 2020
Cancer
FEB 10, 2020
New hope for KRAS-mutant pancreatic cancers
A study published recently in the journal Cancer Research showcases the findings from new research on pancreatic cancer. The study was led by Frank Mc...
Loading Comments...